About

Independent writer and commercial strategist working at the intersection of life science platforms, scientific adoption and AI-enabled discovery. I publish at First Light and work with companies at the boundary between scientific innovation and the commercial organizations that bring these tools into laboratories that use them to advance human health.

In May 2026 I launched First Light, a publication covering life science technology, AI biology, and the markets forming around them. yuzuki.org now serves as an archive of 14 years of writing at The Next Generation Technologist (2012-2024). Current work appears at firstlight.science.

In the summer of 2000, I watched Francis Collins, Craig Venter, and President Bill Clinton announce the first draft of the Human Genome Project. I had first heard about the effort thirteen years earlier as an undergraduate at UCLA. At the time I had no idea that I would spend the next twenty-six years helping bring the technologies born from that project into laboratories around the world.

I joined Illumina in 2003 when the company had roughly eighty employees. Those early years were formative. I learned, first in product management and later in capital equipment sales, that the most important question in scientific commercialization is not what a technology can do, but what a researcher is actually trying to accomplish. Only after understanding that problem can you determine whether a platform truly helps.

That discipline has stayed with me throughout my career. I have worked across several waves of life-science technology: at Life Technologies helping guide a $70 million next-generation sequencing platform transition; at SeraCare developing ctDNA reference standards that later contributed to the company’s acquisition by LGC; at Olink defining market segmentation and messaging for the Explore proteomics platform; and most recently preparing the launch of a next-generation high-plex immunoassay platform.

What distinguishes my commercial work is the scientific foundation underneath it. Before entering industry I spent six years at the bench as a senior research associate at the John Wayne Cancer Institute, first to clone and characterize the cancer antigen MAGE-1. That work resulted in seven peer-reviewed publications, including papers in PNAS and Cancer Research. The experience means that conversations with principal investigators and scientific collaborators are genuine scientific discussions rather than marketing chatter. It changes the nature of a partnership.

During the pandemic I wrote a short book explaining the science behind COVID-19 diagnostics, therapeutics, and vaccines for non-specialist readers. Translating specialized scientific knowledge into clear language is something I believe is both necessary and worthwhile.

The current chapter of my work involves the integration of artificial intelligence into scientific and commercial workflows. I have systematically incorporated AI into day-to-day work: competitive intelligence, investigator research, and prioritizing biomarker hypotheses across tens of thousands of potential protein targets. What once required days of analysis can now often be accomplished in hours, and the frameworks built along the way become reusable tools.

I am most energized at the boundary between science and commercial reality. That boundary, where discovery becomes something scientists actually adopt, is where I have built my career, and where I intend to continue working. I am particularly interested in companies building scientific platforms where advanced biology and AI-enabled analysis are increasingly intertwined.

Writing & Projects

Throughout my career I have also spent time writing and speaking about emerging technologies in the life sciences. Clear explanation matters, especially in fields where complex science intersects with real-world decisions about research and biotechnology.

• Sustained coverage of major life sciences conferences including AGBT, AACR, AMP and ASHG from 2012 to 2023.
• Proteomics in Proximity – podcast conversations exploring emerging proteomics technologies and the scientists developing them.
• Behind the Bench – essays and commentary on life-science technology, commercialization, and the evolution of scientific tools.
• COVID-19 Science Book – a short book explaining the science behind diagnostics, therapeutics, and vaccines during the pandemic.
• Scientific Publications – early research contributions including seven peer-reviewed papers, with publications in PNAS and Cancer Research.

You can find me on LinkedIn. I also co-hosted eighteen episodes of Proteomics in Proximity, a podcast exploring the frontier of protein biomarker discovery.